Drug Profile
Meropenem/vaborbactam - Melinta Therapeutics
Alternative Names: Carbavance™; Meropenem and vaborbactam; Meropenem trihydrate/vaborbactam; Meropenem/RPX-7009; RPX-2014/RPX-7009; RPX-7009/RPX-2014; Vabomere; VaboremLatest Information Update: 12 Jul 2023
Price :
$50
*
At a glance
- Originator Rempex Pharmaceuticals
- Developer Melinta Therapeutics; Menarini; Rempex Pharmaceuticals; US Department of Health and Human Services
- Class Antibacterials; Pyrrolidines; Small molecules; Thienamycins
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Bacteraemia; Bacterial infections; Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Pyelonephritis; Urinary tract infections; Ventilator associated pneumonia
- Phase III Pneumonia
Most Recent Events
- 10 Jul 2023 Melinta Therapeutics receives BARDA grant for meropenem/vaborbactam development in Chronic urinary tract infections
- 10 Jul 2023 Melinta Therapeutics plans to submit sNDA for chronic urinary tract infections (In adolescents, In children) and Sepsis (In neonates)
- 15 May 2023 Oritavancin licensed to Xediton Pharmaceuticals in Canada